Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-402)

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter, observational, retrospective and cross-sectional study to be conducted in a cohort of consecutively selected participants with type 2 diabetes mellitus (T2DM) who have been treated with sulphonylurea (SU) monotherapy or SU + metformin (MF) combination therapy by their cardiologist, nephrologist, or family practice doctor for at least 6 months prior to study enrollment.

The purpose of the study is to assess treatment patterns, goal attainment rates, long-term diabetes complication rates, and frequency and severity of hypoglycemic episodes among T2DM participants treated in cardiology, nephrology and family practice settings.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria

• Participants diagnosed with type 2 diabetes mellitus (DM).

• Participants at least 30 years of age at time of type 2 DM diagnosis.

• Participants treated with SU monotherapy or SU + MF combination therapy for at least 6 months prior to enrollment.

• Participants receiving diabetes care from a cardiologist, nephrologist or family practitioner for at least 6 months.

• Participants with a clinical record in the health care center.

• Participants in whose medical records a minimum core data set can be found; core data defined as: age, gender, duration of diabetes/age at diagnosis, all glucose-lowering medications (branded and generic names, dosage, dosing frequency, starting and stopping dates) since the start of all antihyperglycemic medications.

Exclusion Criteria

• Participants with Type 1 DM.

• Participants who are pregnant or with gestational DM.

• Participants receiving any anti-diabetic treatment from an endocrinologist/diabetologist in the previous 6 months.

• Participants requiring daily concomitant usage of insulin.

• Participants receiving any other oral diabetes medications other than SU or SU + MF.

• Participants who are already participating in a clinical trial or other clinical study.

• Participants for whom it would be impossible to complete the questionnaire.